ReviewCell stress2025
Role of mitochondrial dysfunction in ocular surface diseases.
Review in Cell stress, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Persistent loss of membrane-associated MUC4 reprograms physiological functions in corneal epithelial cells via MAPK-dependent cascade.Scientific reports · 2026Article
- Therapeutic Effects of Glycyrrhizic Acid on Dry Eye Disease: Targeting Pyroptosis, Oxidative Stress, and Epithelial Barrier Dysfunction.International journal of molecular sciences · 2026Article
- Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa.Antioxidants (Basel, Switzerland) · 2026Review
- ELF3 promotes hyperglycemia-induced corneal epithelial senescence and IL-2 attenuates ELF3-associated signaling.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dysfunction of mitochondria, the "energy factories" of cells, not only causes an insufficiency of energy production but also leads to various pathological alterations in cells such as the accumulation of reactive oxygen species, inflammatory responses and mitochondrial DNA damage, all of which were involved in the onset or deterioration of diseases. The presence of mitochondrial dysfunction has been confirmed in many ocular surface diseases such as dry eye, Fuchs corneal endothelial dystrophy and diabetic keratopathy. However, its role in the pathogenesis of ocular surface diseases and underlying molecular mechanisms have not been fully elucidated. Moreover, mitochondrial therapies for ocular surface diseases are currently still under investigation. This mini-review summarizes the pathological features of mitochondrial dysfunction and its mechanisms that have been identified in the pathogenesis of ocular surface diseases, and discusses the potential of mitochondrial therapies in the treatment of these diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.